iBio Reports Preclinical Data on IBIO-610 for Fat-Selective Weight Loss Treatment

iBio has announced new preclinical data from its obese non-human primate study evaluating IBIO-610, a potential first-in-class Activin E antibody candidate. The study demonstrated that IBIO-610 reduced fat mass in obese NHPs compared to vehicle-treated obese NHPs, with a slight up-tick in lean mass. The fat-selective profile is consistent with effects observed in rodents and human clinical trials targeting the Activin E pathway. The data support continued evaluation of IBIO-610's potential as a differentiated therapy in obesity, cardiometabolic, and cardiopulmonary diseases.